Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hodgkin's Lymphomas”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03019640
What this trial is testing

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Mantle Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+4 more
M.D. Anderson Cancer Center 22
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Early research (Phase 1)Active Not RecruitingNCT03478462
What this trial is testing

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Who this might be right for
Pediatric Solid TumorPediatric LymphomaPediatric Brain Tumor+5 more
Cellectar Biosciences, Inc. 30
Testing effectiveness (Phase 2)Study completedNCT03209973
What this trial is testing

Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
BeiGene 70
Early research (Phase 1)Active Not RecruitingNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Testing effectiveness (Phase 2)Study completedNCT01030900
What this trial is testing

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Who this might be right for
Hodgkin LymphomaDiffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Study completedNCT00290498
What this trial is testing

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 67
Testing effectiveness (Phase 2)Study completedNCT00047021
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Case Comprehensive Cancer Center 3
Not applicableStudy completedNCT06119633
What this trial is testing

Implant-based Breast Reconstruction and Mastectomy With Fat Grafting After Breast Conserving Surgery and Radiotherapy

Who this might be right for
Breast Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 163
Testing effectiveness (Phase 2)Study completedNCT00636311
What this trial is testing

A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

Who this might be right for
Hodgkin Disease
Istituto Clinico Humanitas 13
Early research (Phase 1)WithdrawnNCT02640833
What this trial is testing

Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaNon-Hodgkin Lymphoma
AbbVie
Early research (Phase 1)Study completedNCT05564806
What this trial is testing

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Advanced Solid TumorsRelapsed Or Refractory Non-Hodgkin Lymphoma
Eucure (Beijing) Biopharma Co., Ltd 9
Testing effectiveness (Phase 2)Ended earlyNCT00072449
What this trial is testing

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

Who this might be right for
Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Study completedNCT00792467
What this trial is testing

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Who this might be right for
Hodgkin's Lymphoma
Italfarmaco 24
Testing effectiveness (Phase 2)WithdrawnNCT01170052
What this trial is testing

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Mantle Cell Lymphoma
Charite University, Berlin, Germany 20
Large-scale testing (Phase 3)Study completedNCT00877006
What this trial is testing

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Who this might be right for
Non-Hodgkin's LymphomaMantle Cell Lymphoma
Teva Branded Pharmaceutical Products R&D, Inc. 447
Early research (Phase 1)Study completedNCT02594384
What this trial is testing

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
OrphAI Therapeutics 62
Very early researchUnknownNCT04626739
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Who this might be right for
Refractory Indolent Adult Non-Hodgkin Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT00066092
What this trial is testing

Pegfilgrastim PBPC Mobilization Study

Who this might be right for
LymphomaHodgkin's LymphomaNon-Hodgkin's Lymphoma+2 more
Amgen 41
Not applicableLooking for participantsNCT07652580
What this trial is testing

Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaLymphoma Non-HodgkinB-cell Lymphoma+1 more
Henry M. Jackson Foundation for the Advancement of Military Medicine 300
Next Page